Access to anti-retroviral drugs, female in World

World: Access to anti-retroviral drugs, female was 83.0% in 2024. ◆ Volatile

Latest (2024)
83.0%
Change on year
up 2.5%
Rank
15th
of 19 groups
All-time high
83.0%
in 2024
All-time low
1.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, female in World, 2000–2024

0204060802000201220242000: 1 %2001: 1 %2002: 1 %2003: 2 %2004: 3 %2005: 5 %2006: 7 %2007: 11 %2008: 15 %2009: 19 %2010: 25 %2011: 31 %2012: 37 %2013: 42 %2014: 47 %2015: 52 %2016: 58 %2017: 64 %2018: 67 %2019: 70 %2020: 73 %2021: 76 %2022: 78 %2023: 81 %2024: 83 %

Source: UNAIDS estimates. Measured in %.

Analysis

World recorded 83.0% for access to anti-retroviral drugs, female in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 2.5% on the previous year and up 76.6% over ten years.

Over the whole period, access to anti-retroviral drugs, female in World peaked at 83.0% in 2024 and was at its lowest, 1.0%, in 2000.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, female in World, year by year

Annual values for Access to anti-retroviral drugs, female (%) in World, 2000 to 2024.
Year % Change
2000 1.0%
2001 1.0% +0.0%
2002 1.0% +0.0%
2003 2.0% +100.0%
2004 3.0% +50.0%
2005 5.0% +66.7%
2006 7.0% +40.0%
2007 11.0% +57.1%
2008 15.0% +36.4%
2009 19.0% +26.7%
2010 25.0% +31.6%
2011 31.0% +24.0%
2012 37.0% +19.4%
2013 42.0% +13.5%
2014 47.0% +11.9%
2015 52.0% +10.6%
2016 58.0% +11.5%
2017 64.0% +10.3%
2018 67.0% +4.7%
2019 70.0% +4.5%
2020 73.0% +4.3%
2021 76.0% +4.1%
2022 78.0% +2.6%
2023 81.0% +3.8%
2024 83.0% +2.5%

Averages by decade

DecadeAverage LowestHighest Years
2000s 6.5% 1.0% 19.0% 10
2010s 49.3% 25.0% 70.0% 10
2020s 78.2% 73.0% 83.0% 5

Countries ranked near World

  1. 12 Rwanda 97.0% compare
  2. 12 United Arab Emirates 97.0% compare
  3. 14 Liberia 96.0% compare
  4. 14 Sweden 96.0% compare
  5. 14 Togo 96.0% compare
  6. 14 United Kingdom of Great Britain and Northern Ireland 96.0% compare
  7. 14 Zambia 96.0% compare

See the full ranking of 160 places →

More gender data for World

All data for World →

Frequently asked questions

What is access to anti-retroviral drugs, female in World?
Access to anti-retroviral drugs, female in World was 83.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, female recorded in World?
The highest recorded value was 83.0% in 2024.
What is the lowest access to anti-retroviral drugs, female recorded in World?
The lowest recorded value was 1.0% in 2000.
How does World rank for access to anti-retroviral drugs, female?
World ranks 15th out of 19 groups with data for 2024.
Is access to anti-retroviral drugs, female rising or falling in World?
Over the last ten years it is up 76.6%. The long-run trend across the full record is volatile.
Where does this World data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, female (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, female in World. Statizoid, drawing on UNAIDS estimates. Retrieved 07 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/world/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-female-percent/world/">Access to anti-retroviral drugs, female in World</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, female (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,925 data points, 2000–2024
Last refreshed

The percentage of adult females living with HIV who are receiving antiretroviral therapy.